Treatment outcome of thalidomide based regimens in newly diagnosed and relapsed/refractory non-transplant multiple myeloma patients: a single center experience from Thailand

Table 1 Patients' characteristics and treatment outcomes of previously untreated and relapsed/refractory multiple myeloma

Characteristics		ORR		CR/VGPR		PFS			OS
Characteristics	Total patients (N = 42)	No. of Patients %	p-value	No. of patients	p-value	HR	95% CI	p-value	HR	95% CI	p-value
Age (years), median (range)	62,(36-75)
≤ 60	17	15(94)	0.83	9(56.3)	0.45	2.95	0.98-8.81	0.05	0.81	0.09-7.27	0.85
> 60	25	23(92)		17(68)
Sex
Male	21	18(85.7)	0.79	13(65)	0.91	0.77	0.25-2.38	0.65	2.06	0.34-12.68	0.44
Female	21	20(95.2)		14(66.7)
Prior treatment
Yes	29	26(92.6)	0.95	19(67.9)	0.69	3.68	0.91-10.28	0.06	0.87	0.96-7.88	0.9
No	13	12(92.3)		8(61.5)
International staging system
I, II	8, 18	24(92.3)	0.97	15(57.7)	0.93	6.30	0.73-54.01	0.09	2.22	0.20-24.57	0.51
III	13	12(92.3)		8(61.5)
No data	3
M-protein subtype
IgG, IgA, IgM	23, 8, 1	27(87.1)	0.32	19(61.3)	0.86	3.19	0.64-15.91	0.16	1.21	0.13-11.65	0.87
Kappa, Lamda	3, 6	9(100)		6(66.7)
Unknown type	1
Serum creatinine level
< 2 mg/dl	34	31(91.2)	0.43	22(64.7)	0.57	0.74	0.08-6.72	0.79	0.03	0.01-856.9	0.50
≥ 2 mg/dl	8	7(100)		4(57.2)
Serum β2 M level, μg/ml
≤ 5	26	24(92.3)	0.53	17(65.4)	0.79	4.89	0.55-43.88	0.16	1.97	0.18-21.81	0.58
> 5	13	11(84.6)		8(61.5)
No data	3
Response to treatment
Yes	38	-	-	-	-	0.15	0.04-0.61	0.01	0.03	0.01-0.35	0.01
No	3
CR/VGPR
Yes	26	-	-	-	-	0.14	0.04-0.47	0.01	0.21	0.03-1.48	0.12
No	15

ISSN: 1756-8722